Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Editorial

Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”

Chih-Wen Wang, Ming-Lung Yu

Clin Mol Hepatol. 2025;31(2):606-609. Published online December 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.1078

View: 601 Download: 22 Crossref: 1

Lamivudine: fading into the mists of time

Jonggi Choi, Young-Suk Lim

Clin Mol Hepatol. 2017;23(4):314-315. Published online November 28, 2017

DOI: https://doi.org/10.3350/cmh.2017.0110

View: 6352 Download: 125

Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?

Nae-Yun Heo

Clin Mol Hepatol. 2017;23(2):125-127. Published online June 23, 2017

DOI: https://doi.org/10.3350/cmh.2017.0106

View: 7890 Download: 145 Web of Science: 3 Crossref: 3

Original Article

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients

Sang Kyung Jung, Kyung-Ah Kim, So Young Ha, Hyun Kyo Lee, Young Doo Kim, Bu Hyun Lee, Woo Hyun Paik, Jong Wook Kim, Won Ki Bae, Nam-Hoon Kim, June Sung Lee, Yoon Jung Jwa

Clin Mol Hepatol. 2015;21(1):41-48. Published online March 25, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.1.41

View: 9364 Download: 86 Web of Science: 17 Crossref: 12

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients

Young Jip Kim, Kichan Kim, Sun Hyuk Hwang, Soon Sun Kim, Dami Lee, Jae Youn Cheong, Sung Won Cho

Clin Mol Hepatol. 2013;19(3):300-304. Published online September 30, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.3.300

View: 8361 Download: 87 Crossref: 27

Impact of components of metabolic syndrome on long-term outcomes of CHB with nucleos(t)ide analogue treatment

Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Atsukawa, Hirokazu Takahashi, Kunihiko Tsuji, Koichi Takaguchi, Pei-Chien Tsai, Chia-Yen Dai, Jee-Fu Huang, Chung-Feng Huang, Ming-Lun Yeh, Eileen Yoon, Sung Eun Kim, Sang Bong Ahn, Gi-Ae Kim, Jang Han Jung, Soung Won Jeong, Hyunwoo Oh, Cheng-Hao Tseng, Masatoshi Ishigami, Angela Chau, Mayumi Maeda, Satoshi Yasuda, Makoto Chuma, Takanori Ito, Keigo Kawashima, Joanne Kimiko Liu, Adrian Gadano, Ritsuzo Kozuka, Norio Itokawa, Kaori Inoue, Tomonori Senoh, Jie Li, Wan-Long Chuang, Ramsey Cheung, Chao Wu, Ming-Lung Yu, Mindie H. Nguyen

Received November 27, 2024 Accepted March 14, 2025

DOI: https://doi.org/10.3350/cmh.2024.1070 [Accepted]

View: 836 Download: 66

1 |

Viewed By 8481	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7419	MAFLD: How is it different from NAFLD?
Viewed By 5377	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5007	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4550	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 319	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 291	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 186	MAFLD: How is it different from NAFLD?
Cited By 101	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 92	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search